ES2196053T3 - Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos. - Google Patents

Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.

Info

Publication number
ES2196053T3
ES2196053T3 ES95904697T ES95904697T ES2196053T3 ES 2196053 T3 ES2196053 T3 ES 2196053T3 ES 95904697 T ES95904697 T ES 95904697T ES 95904697 T ES95904697 T ES 95904697T ES 2196053 T3 ES2196053 T3 ES 2196053T3
Authority
ES
Spain
Prior art keywords
glutamine
liver
treatment
administration
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95904697T
Other languages
English (en)
Inventor
Leeuwen Paulus Aloisius Ma Van
Alexander Petrus Jacob Houdijk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STICHTING ZOFIA
Original Assignee
STICHTING ZOFIA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2196053(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by STICHTING ZOFIA filed Critical STICHTING ZOFIA
Application granted granted Critical
Publication of ES2196053T3 publication Critical patent/ES2196053T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE GLUTAMINA O DE UN EQUIVALENTE DE GLUTAMINA PARA EL TRATAMIENTO DE ESTADOS ENFERMOS DONDE HAY UN FLUJO SANGUINEO REDUCIDO AL HIGADO O DONDE HAY BAJOS NIVELES DE PLASMA DE ARGININA. DICHOS ESTADOS ENFERMOS COMPRENDEN ENDOTOXEMIA, INFLAMACION SISTEMICA, ALTO NIVEL DE ARGINASA EN PLASMA, BACTEREMIA, ICTERICIA, TRASPLANTE DE HIGADO, RESECCION DEL HIGADO, ENFERMEDAD INTESTINAL INFLAMATORIA, TRASPLANTES EN GENERAL, AUMENTO DE PRODUCCION DE CITOQUINA O ESTEATOSIS DEL HIGADO. TAMBIEN SE PROPORCIONA UNA COMPOSICION ALIMENTICIA ADECUADA PARA MEJORAR LA FUNCION DEL HIGADO, QUE CONTIENE, COMO UNIDAD DE DOSIFICACION DIARIA, DE 15-300 G DE GLUTAMINA O DE UN EQUIVALENTE DE GLUTAMINA, JUNTO A UNA CANTIDAD DE HIDRATOS DE CARBONO, PROTEINAS, LIPIDOS, VITAMINAS, MINERALES Y FIBRAS VEGETALES, LO CUAL ES SUFICIENTE PARA CUMPLIR UN REQUISITO ALIMENTICIO MINIMO DIARIO.
ES95904697T 1994-01-11 1995-01-11 Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos. Expired - Lifetime ES2196053T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94200042 1994-01-11

Publications (1)

Publication Number Publication Date
ES2196053T3 true ES2196053T3 (es) 2003-12-16

Family

ID=8216591

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95904697T Expired - Lifetime ES2196053T3 (es) 1994-01-11 1995-01-11 Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.

Country Status (5)

Country Link
US (1) US6001878A (es)
EP (2) EP0738146B1 (es)
DE (1) DE69530570T2 (es)
ES (1) ES2196053T3 (es)
WO (1) WO1995018608A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041216A1 (en) * 1997-03-17 1998-09-24 Tam Yun K Composition for prevention of hepatic steatosis
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US7431939B1 (en) 2000-09-28 2008-10-07 Mississippi State University Inhibition of systemic infections in humans and vertebrates by dietary fibers
GB2371767A (en) * 2001-02-02 2002-08-07 Labman Automation Ltd Dissolving materials by application of agitation and ultrasound
EP1663283B1 (en) * 2003-09-12 2012-05-23 University of Colorado Glutamine for use in treating injury
US20050124694A1 (en) * 2003-12-09 2005-06-09 Arthur Vanmoor Method of accelerating metabolism of alcohol
US20080166323A1 (en) * 2004-04-14 2008-07-10 Uab Research Foundation Activators of Hexosamine Biosynthesis as Inhibitors of Injury Induced by Ischemia or Hermorrhagic Shock
US8445536B2 (en) * 2005-03-31 2013-05-21 Ajinomoto Co., Inc. Arginine-containing compositions and methods for increasing blood flow using same
JP5046174B2 (ja) * 2005-03-31 2012-10-10 味の素株式会社 アルギニン含有血流増加用組成物
WO2008038771A1 (fr) 2006-09-29 2008-04-03 Ajinomoto Co., Inc. Composition contenant de la glutamine destinée à augmenter le flux sanguin
BR112014014765A8 (pt) * 2011-12-19 2017-07-04 Emmaus Medical Inc métodos e composições para o tratamento da diverticulose
EP2612560A1 (en) * 2012-01-09 2013-07-10 N.V. Nutricia Glutamine enriched nutritional composition for preterm infants
EP2802223B1 (en) * 2012-01-09 2017-05-03 N.V. Nutricia Glutamine enriched nutritional composition for preterm infants
JP7082258B2 (ja) 2016-02-01 2022-06-08 バイオエナジー ライフ サイエンス，インコーポレイティド うっ血性心不全に罹っている対象を治療するためのリボースの使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
JPS61186320A (ja) * 1985-02-12 1986-08-20 Morishita Seiyaku Kk アミノ酸製剤
CA1285491C (en) * 1985-09-12 1991-07-02 Robert J. Smith Method of treating catabolic dysfunction
JPH01216924A (ja) * 1988-02-24 1989-08-30 Ajinomoto Co Inc 肝障害治療剤
IL94549A (en) * 1989-06-02 1996-08-04 Brigham & Womens Hospital A pharmaceutical preparation containing glutamine
US5157022A (en) * 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5248697A (en) * 1990-09-20 1993-09-28 Brigham And Women's Hospital Enhancement of glutathione levels with glutamine
SE468881B (sv) * 1991-01-09 1993-04-05 Kabi Pharmacia Ab Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar
DE9110794U1 (es) * 1991-08-31 1991-10-31 Grabarkiewicz, Gerda, 8520 Erlangen, De
JP3168669B2 (ja) * 1992-02-26 2001-05-21 味の素株式会社 肝再生促進剤
US5438042B1 (en) * 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile

Also Published As

Publication number Publication date
DE69530570D1 (de) 2003-06-05
EP0738146B1 (en) 2003-05-02
US6001878A (en) 1999-12-14
WO1995018608A1 (en) 1995-07-13
EP1362587A1 (en) 2003-11-19
EP0738146A1 (en) 1996-10-23
DE69530570T2 (de) 2004-03-18

Similar Documents

Publication Publication Date Title
ES2196053T3 (es) Procedimiento para el tratamiento de trastornos del cuerpo humano o animal mediante la administracion de aminoacidos.
Li et al. Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes
Frick et al. Dose response and minimal daily requirement for vitamin K in man.
Kon et al. Non-surgical management of early knee osteoarthritis
PT1131065E (pt) Fumaratos dialquilicos para o tratamento de doencas autoimunes
Murillo Ortiz et al. Recovery of bone and muscle mass in patients with chronic kidney disease and iron overload on hemodialysis and taking combined supplementation with curcumin and resveratrol
ATE333275T1 (de) Indole-3-propionsäure, ihre salze und ester als arzneimittel
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
ECSP066873A (es) Compuestos hmb y usos parecidos
BR0106681A (pt) Fórmula pediátrica e métodos para prover nutrição a pacientes pediátricos e para melhorar tolerância em pacientes pediátricos
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR9906438A (pt) Composição de reforço nutricional apropriada para o tratamento de úlceras de pressão
ES2080307T3 (es) Composiciones farmaceuticas.
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
Pereira et al. Anti-arthritic properties of crude extract from Chenopodium ambrosioides L. leaves
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
ATE293895T1 (de) Faserige lipo-ernährungskomplexe und diese enthaltende zusammensetzungen
da Silva et al. Bromelain: A potential strategy for the adjuvant treatment of periodontitis
US20110045099A1 (en) Nutraceutical composition and methods of use
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
DE3750426D1 (de) Mittel zur Verbesserung spezifischer Eigenschaften des Blutes.
Schmid-Schönbein A journey with Tony Hugli up the inflammatory cascade towards the auto-digestion hypothesis
Imafidon et al. Protective effect of ethanolic extract of Palisota hirsute on CCl4 induced hepatotoxicity